Development and evaluation of a Sarcocystis neurona-specific IgM capture enzyme-linked immunosorbent assay.
Authors: Murphy J E, Marsh A E, Reed S M, Meadows C, Bolten K, Saville W J A
Journal: Journal of veterinary internal medicine
Summary
# Editorial Summary: IgM Capture ELISA for Equine Protozoal Myeloencephalitis Diagnosis Equine protozoal myeloencephalitis (EPM), caused by *Sarcocystis neurona*, remains a significant neurological threat to horses, yet current antemortem diagnostic tests suffer from poor specificity, making early and reliable detection problematic. Murphy and colleagues developed and validated a novel IgM capture ELISA targeting the *S. neurona*-specific low molecular weight protein SNUCD-1, testing serum and cerebrospinal fluid (CSF) samples from two cohorts of experimentally infected horses (one group receiving 1.5 million sporocysts, a second receiving doses ranging from 100 to 100,000 sporocysts). Horses challenged with the higher inoculation dose showed significantly elevated serum IgM concentrations at weeks 2–6 post-infection (*P* < 0.0001), whilst those receiving lower doses demonstrated dose-dependent temporal increases in serum IgM (*P* < 0.01); importantly, CSF IgM concentrations also rose significantly following infection (*P* < 0.0001). These findings suggest the assay has genuine potential for identifying EPM during its acute phase, when therapeutic intervention is most likely to succeed, offering practitioners a more specific diagnostic option than currently available alternatives—though further field validation in naturally infected populations will be essential before clinical adoption.
Read the full abstract on PubMed
Practical Takeaways
- •An IgM capture ELISA may improve early diagnosis of EPM during acute infection when serum and CSF samples show elevated Sn-IgM, addressing the low specificity of currently available tests
- •Testing should be performed 2-6 weeks post-infection for optimal detection in serum; CSF analysis may provide additional diagnostic value
- •This assay could enable earlier clinical diagnosis of EPM, potentially allowing more timely therapeutic intervention before severe neurological damage occurs
Key Findings
- •Serum Sn-IgM concentrations increased significantly 2-6 weeks after inoculation with 1.5 million sporocysts (P < 0.0001)
- •IgM capture ELISA based on SNUCD-1 antigen successfully detected S. neurona-specific antibodies in both serum and cerebrospinal fluid
- •Lower challenge doses (100-100,000 sporocysts) produced dose-dependent increases in serum Sn-IgM at various timepoints post-infection (P < 0.01)
- •Cerebrospinal fluid Sn-IgM concentrations showed significant increases before and after inoculation (P < 0.0001)